Overview

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
Allo-HSCT is the most effective way to cure MDS and AML secondary to MDS. At present, the best conditioning regimen for MDS and AML secondary to MDS undergoing allo-HSCT remains in discussion. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in RAEB-1, REAB-2 and AML secondary to MDS undergoing allo-HSCT are evaluated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First Affiliated Hospital of Guangxi Medical University
First People's Hospital of Chenzhou
Guangzhou First People's Hospital
Institute of Hematology and Blood Diseases Hospital
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Third Affiliated Hospital, Sun Yat-Sen University
Treatments:
Busulfan
Cyclophosphamide
Decitabine
Fludarabine
Lenograstim
Sargramostim